Biopharmaceutical company developing therapeutics for aging-related diseases.
resTORbio, Inc. (NASDAQ:TORC) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases.
The decline in immune function that occurs during aging, or immunosenescence, increases susceptibility to a variety of diseases that significantly contribute to morbidity and mortality in the elderly. resTORbio’s lead program has demonstrated in several clinical trials, including a randomized, placebo-controlled trial, the potential to treat multiple diseases of aging for which there are no approved therapies. resTORbio's approach focuses on the mechanistic target of rapamycin (mTOR) pathway, an evolutionarily conserved pathway that regulates aging, and specifically on selective inhibition of the target of rapamycin complex 1, or TORC1.
Visit website: http://www.restorbio.com/
People at resTORbio
mTOR inhibitors reversed immune ageing to treat viral infections in older adults
Lifespan.io (LEAF) - 21-May-2021
Much needed approach to improve immune function during the COVID pandemicRead more...
Super summary of 3rd Annual Longevity Therapeutics Summit
Lifespan.io (LEAF) - 16-Feb-2021
More and more companies making greater and greater progress - 2021 could be an exciting yearRead more...
Adicet merges with resTorbio for CAR T-cell therapy pipeline funding
FierceBiotech - 30-Apr-2020
The deal moves company forward to initiating phase 1 trials in non-Hodgkin lymphoma next yearRead more...
Longevity Leaders' latest report on how longevity is disrupting the world
Longevity Leaders (LSX) - 01-Jan-2020
An interesting collection of interviews and white-papers with industry leadersRead more...
resTORbio Agrees Phase 3 Human Trials with FDA
Lifespan.io (LEAF) - 19-Mar-2019
If successful, drug could be available in next few yearsRead more...
Is This the Anti-Aging Pill We’ve All Been Waiting For?
MIT Technology Review - 28-Mar-2017
Novartis sought to see whether giving low doses of everolimus to people over 65 increased their r...Read more...